Cel Sci (CVM) FCF Margin (2010 - 2017)
Cel Sci (CVM) posted FCF Margin of 17972.71% for Q2 2017, down 331.33% sequentially from 4166.82% in Q2 2016, and down 1380588.0% YoY from N/an in Q2 2016.
Cel Sci (CVM) FCF Margin (2010 - 2017) Analysis & Trends
Cel Sci has reported FCF Margin for 4 years, with the latest figure at 17972.71% in Q2 2017.
- Quarterly FCF Margin fell 1380588.0% year-over-year to 17972.71% in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 4346.19% (down 29478.0% YoY) and the FY2011 annual result came in at 2381.64%, up 629281.0% from the prior year.
- FCF Margin retreated to 17972.71% in Q2 2017 per CVM's latest filing, from 4166.82% in the prior quarter.
- Over five years, FCF Margin peaked at 4166.82% in Q2 2016 and troughed at 17972.71% in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -17,972.71% |
| Jun 30, 2016 | -4,166.82% |
| Sep 30, 2011 | -2,831.17% |
| Jun 30, 2011 | -9,372.29% |
| Sep 30, 2010 | -3,001.67% |